---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-028611"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2023-06-16T23:59:59+00:00"
generated_at: "2026-06-13T22:49:45.287017+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Intellia Therapeutics stockholders approve doubling of authorized shares to 240M

## Summary
- Stockholders approved amendment to increase authorized common shares from 120M to 240M.
- Three Class I directors elected: Muna Bhanji, John F. Crowley, Jesse Goodman.
- Deloitte & Touche ratified as independent auditor for fiscal year 2023.
- Advisory say-on-pay vote approved with 65.8M for, 1.2M against.
- Amendment filed with Delaware Secretary of State on June 14, 2023.

## SEC filing metadata
- accession: 0000950170-23-028611
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2023-06-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000095017023028611/0000950170-23-028611-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000095017023028611/ntla-20230614.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-028611
- JSON: https://secwatch.observer/filing/0000950170-23-028611.json
- Plain text: https://secwatch.observer/filing/0000950170-23-028611.txt

## Key facts
- Governance Changes
  Intellia Therapeutics, Inc.: Increased authorized shares of common stock from 120,000,000 to 240,000,000 (effective 2023-06-14).
  - Change: charter amendment
  - Effective: 2023-06-14
  source text: On June 14, 2023, Intellia Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment (the “Amendment”) to the Company’s Second Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to increase the number of authorized shares of common stock from 120,000,000 to 240,000,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000095017023028611/0000950170-23-028611-index.htm
- Shareholder Votes
  Intellia Therapeutics, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2023-06-14 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-14
  source text: The stockholders of the Company approved, on an advisory basis, the compensation of the named executive officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000095017023028611/0000950170-23-028611-index.htm
- Shareholder Votes
  Intellia Therapeutics, Inc. shareholders approved Amendment to Certificate of Incorporation to increase authorized shares from 120,000,000 to 240,000,000 at the 2023-06-14 meeting.
  - Proposal: charter amendment
  - Outcome: passed
  - Meeting: 2023-06-14
  source text: The stockholders of the Company approved and adopted an amendment to the Company’s Second Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 120,000,000 to 240,000,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000095017023028611/0000950170-23-028611-index.htm
- Shareholder Votes
  Intellia Therapeutics, Inc. shareholders approved Election of Class I Directors at the 2023-06-14 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-14
  source text: The stockholders of the Company elected Muna Bhanji, R.Ph., John F. Crowley and Jesse Goodman, M.D., M.P.H. as class I directors, for a three-year term ending at the annual meeting of stockholders to be held in 2026 and until his or her successor has been duly elected and qualified or until his or her earlier resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000095017023028611/0000950170-23-028611-index.htm
- Shareholder Votes
  Intellia Therapeutics, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm at the 2023-06-14 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-14
  source text: The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000095017023028611/0000950170-23-028611-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.